ABVX vs ARRY vs PTGX vs PRTA vs ARDX vs JPM vs KO

For growth investors, Array Technologies, Inc.

(ARRY) is the stronger pick with 40. 2% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Abivax S. A. (ABVX) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 6x versus The Coca-Cola Company at 27. 1x. On forward P/E, Array Technologies, Inc. is actually cheaper at 10. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 08x versus The Coca-Cola Company's 2. 26x — a reasonable growth-adjusted valuation.

Over the past 5 years, Abivax S.

A. (ABVX) delivered a total return of +1115%, compared to -81. 7% for Prothena Corporation plc (PRTA). Over 10 years, the gap is even starker: ABVX returned +1063% versus PRTA's -82. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Array Technologies, Inc. 's 2. 47β — meaning ARRY is approximately -1333% more volatile than KO relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 3% for Array Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Array Technologies, Inc.

(ARRY) is pulling ahead at 40. 2% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Array Technologies, Inc. grew EPS 62. 6% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 08x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Array Technologies, Inc. (ARRY) trades at 10. 2x forward P/E versus 176. 7x for Prothena Corporation plc — 166. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 193. 6% to $17. 00.

In this comparison, KO (2.

5% yield), JPM (1. 9% yield) pay a dividend. ABVX, ARRY, PTGX, PRTA, ARDX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Array Technologies, Inc. (ARRY) carries a higher beta of 2. 47 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, ARRY: -78. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ABVX (Healthcare) and ARRY (Energy) and PTGX (Healthcare) and PRTA (Healthcare) and ARDX (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ABVX is a small-cap quality compounder stock; ARRY is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; PRTA is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. JPM, KO pay a dividend while ABVX, ARRY, PTGX, PRTA, ARDX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.